| Trial Identifier: | D5083C00002 |
| Sponsor: | AstraZeneca |
| NCTID:: | NCT05374603 |
| Start Date: | November 2022 |
| Primary Completion Date: | October 2024 |
| Study Completion Date: | December 2024 |
| Condition: | Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
| Country | Location |
|---|---|
| CN | Beijing, CN, 100021 |
| CN | Beijing, CN, 100039 |
| CN | Beijing, CN, CN-100730 |
| CN | Changsha, CN, 410011 |
| CN | Chongqing, CN, 400010 |
| CN | Hangzhou, CN, 310009 |
| CN | Hangzhou, CN, 310003 |
| CN | Jinan, CN, 250021 |
| CN | Kunming, CN, 650118 |
| CN | Nanchang, CN, 330006 |
| CN | Ningbo, CN, 315100 |
| CN | Shanghai, CN, 200030 |
| CN | Wenzhou, CN, 325000 |
| CN | Wuhan, CN, 430030 |
| CN | Wuhan, CN, 430022 |
| CN | Zhengzhou, CN, 450000 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company